Generic Wegovy is here: Sevmia approved in Canada
Health Canada approved Sevmia from Apotex on June 29, 2026. It is the first generic referencing Wegovy. Track regulatory status, published price information, and pharmacy availability below.
Last updated: September 16, 2026
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Advertisement
Latest update · September 16, 2026
Health Canada approved Sevmia from Apotex on June 29, 2026, the first generic referencing Wegovy. Read the Health Canada announcement → Ontario now publishes a Sevmia price listing. Retail pricing and pharmacy stock remain unconfirmed; see the details below.
Generic semaglutide product status
Approved means authorized for sale. Marketed is Health Canada's recorded market status, not confirmation that a particular pharmacy has stock. We have not verified local stock for the products below.
| Product and manufacturer | Health Canada status | Price information |
|---|---|---|
| Apo-Semaglutide InjectionApotexHealth Canada DIN records:0256801202568020 | MarketedMay 14, 2026 | See pharmacy price listings |
| Semaglutide InjectionDr. Reddy's LaboratoriesHealth Canada DIN records:0256780602567814 | MarketedMay 6, 2026 | Retail quote not verified for this update |
| SevmiaApotexHealth Canada DIN records:02569582 | ApprovedJune 29, 2026 | Ontario listing: $325.0480 CAD. Retail quote unconfirmed. |
| Aspen-SemaglutideAspen Pharmacare CanadaHealth Canada DIN records:0256993002569949 | ApprovedJuly 17, 2026 | Retail quote not verified for this update |
| Semaglutide InjectionAspen Pharmacare CanadaHealth Canada DIN records:0257091202570920 | ApprovedAugust 25, 2026 | Retail quote not verified for this update |
Multiple DINs or product names from the same company do not represent separate manufacturers.
Approval timeline
Based on publicly available Health Canada filings and regulatory timelines.
April 28, 2026
Health Canada approved Dr. Reddy's Semaglutide Injection, the first generic semaglutide authorized in Canada.
May 1, 2026
Health Canada approved Apo-Semaglutide Injection from Apotex.
June 29, 2026
Health Canada approved Sevmia from Apotex, the first generic referencing Wegovy. The earlier Dr. Reddy’s and Apo-Semaglutide products reference Ozempic.
July 17, 2026
Health Canada records approval of Aspen-Semaglutide from Aspen Pharmacare Canada, DINs 02569930 and 02569949. Approval does not confirm pharmacy stock. Source records are linked in the product table above.
August 25, 2026
Health Canada records approval of two Aspen Semaglutide Injection listings, DINs 02570912 and 02570920. These are additional records from the same manufacturer. Source records are linked in the product table above.
Timeline is based on public information only. GLP1Prices does not have advance knowledge of Health Canada decisions.
Health Canada's July 31, 2026 GSUR snapshot listed nine semaglutide submissions from eight companies. This is a dated snapshot, not today's pending total; later approvals cannot simply be subtracted from it. Read Health Canada's submissions list.
How generic pricing tiers work
The pan-Canadian Pharmaceutical Alliance's tiered pricing framework applies to eligible generic products whose brand reference product is or was eligible for reimbursement by a participating public drug plan. The pCPA assesses the applicable tier; this table does not assign a tier to any semaglutide product.
| Competing manufacturers | Framework price |
|---|---|
| One, where a brand pricing agreement exists or existed | 75% of the brand reference price at market entry, then 55% after three months of public funding in each jurisdiction |
| One, where no brand pricing agreement has ever existed | 85% of the brand reference price |
| Two | 50% of the brand reference price |
| Three or more, for injectables and other non-oral-solid forms | 35% of the brand reference price |
Count competing manufacturers in the relevant price category, not approved product names or DINs. Approval alone does not establish competition; the framework also considers market status and supply. The three-month clock starts with public funding in each jurisdiction, not Health Canada approval.
Pharmacy fees, markups and coverage affect what you pay. These percentages do not predict your retail bill or guarantee coverage. Read the pCPA framework.
Advertisement
Need a prescription? You can get it online
Licensed Canadian practitioners review your case online. Free delivery. $0 consult fee.
Generic Wegovy in Canada: what Sevmia is
Sevmia is a generic semaglutide product from Apotex that references Wegovy. Health Canada approved it on June 29, 2026. Apotex's earlier Apo-Semaglutide Injection and Dr. Reddy's Semaglutide Injection reference Ozempic. The product table above separates their regulatory status from pharmacy availability.
Sevmia price listing and availability
Ontario lists $325.0480 CAD in its Drug Benefit Price or Unit Price field for Sevmia, 4 mg/3 mL in a 3 mL prefilled pen, DIN 02569582. The entry was listed on August 31, 2026. See Ontario's listing.
The entry is Off-Formulary Interchangeable, with Amount MOH Pays shown as N/A. This published listing is not a verified retail quote or confirmation of public coverage. Health Canada lists Sevmia as Approved; we have not confirmed pharmacy stock. Health Canada product record.
Retail price and pharmacy stock unconfirmed. Check back, or join the free alert to follow Sevmia pricing updates. See the full Sevmia cost guide for the pricing outlook in detail.
New approvals are clearing. Don't miss the next one.
Get notified when additional generic semaglutide products are approved and prices are listed in Canada.
Track generic semaglutide prices at Canadian pharmacies
Apo-Semaglutide launched in May 2026. Get notified when it's available at your pharmacy or when prices change.
What you'll receive
- Email notification when additional generic semaglutide prices are listed
- Price comparison across Canadian pharmacies — in your province
- No spam — one email when prices are live, unsubscribe any time